Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

New ADC agreement launched
May 2018
SHARING OPTIONS:

CAMBRIDGE, Mass. & LADENBURG, Gemany—An exclusive multitarget research agreement is underway between Magenta Therapeutics Inc. and Heidelberg Pharma AG to combine Magenta’s stem cell platform with antibodies across as many as four exclusive targets and Heidelberg Pharma’s Antibody Targeted Amanitin Conjugates platform. Per the agreement, Magenta will gain access to Heidelberg Pharma’s Amanitin toxin-linker platform technology, and will have an option for an exclusive target-specific license for global development and commercialization rights to each product candidate that results from this deal. For its part, Heidelberg Pharma gains upfront technology access as well as exclusivity fees and payments for research support. Heidelberg also stands to receive option fees and clinical development, regulatory and sales-related milestone payments worth up to $334 million if Magenta exercises its options and all milestones are reached.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.